Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;47(1):343-359.
doi: 10.1007/s13402-023-00871-0. Epub 2023 Sep 6.

Overexpressed FAM111B degrades GSDMA to promote esophageal cancer tumorigenesis and cisplatin resistance

Haiqin Wang  1   2 , Haohui Wang  3   4 , Jiajing Chen  1   2 , Pian Liu  5   6 , Xiaoxiong Xiao  7   8   9
Affiliations

Overexpressed FAM111B degrades GSDMA to promote esophageal cancer tumorigenesis and cisplatin resistance

Haiqin Wang et al. Cell Oncol (Dordr). 2024 Feb.

Abstract

Background: Chemotherapeutic agents such as cisplatin are commonly used in patients with clinically unresectable or recurrent esophageal cancer (ESCA). However, patients often develop resistance to cisplatin, which in turn leads to a poor prognosis. Studies have shown that FAM111B may be involved in the development of tumors as an oncogene or tumor suppressor gene. However, the pathological role and corresponding mechanism of FAM111B in ESCA are still unclear.

Methods: The GEPIA web tool, ENCORI Pan-Cancer Analysis Platform and UALCAN-TCGA database were used to study the expression of FAM111B in ESCA. CCK-8, angiogenesis, Transwell and xenograft assays were applied to explore the biological function of FAM111B in ESCA. Western blot, RT-qPCR, and RNA-seq analyses were applied to study the FAM111B/GSDMA axis in the progression of ESCA cells. CCK-8 and xenograft assays were used to study the role of the FAM111B/GSDMA axis in determining the sensitivity of ESCA to cisplatin.

Results: Our results demonstrated that FAM111B is highly expressed in ESCA tissues compared to normal tissues. We showed that FAM111B promotes the progression of ESCC cells by binding to GSDMA and that the trypsin protease domain is essential for the activity of FAM111B. Furthermore, we showed that the FAM111B/GSDMA axis regulates cisplatin sensitivity in ESCA.

Conclusions: Overall, we identified a novel FAM111B/GSDMA axis regulating ESCA tumorigenesis and chemosensitivity, at least in ESCC cells.

Keywords: Cisplatin; Esophageal cancer; FAM111B; GSDMA.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. H.C. Puhr, G.W. Prager, A. Ilhan-Mutlu, How we treat esophageal squamous cell carcinoma. ESMO Open 8(1), 100789 (2023) - DOI - PubMed - PMC
    1. M. Sheikh et al., Current status and future prospects for esophageal cancer. Cancers (Basel) 15(3), 765 (2023)
    1. J. An et al., Natural products for esophageal cancer therapy: from traditional medicine to modern drug discovery. Int J Mol Sci 23(21), 13558 (2022)
    1. Y. Baba et al., Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci 111(9), 3132–3141 (2020) - DOI - PubMed - PMC
    1. Y. Jia et al., Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin. Mol Cancer 20(1), 162 (2021) - DOI - PubMed - PMC

LinkOut - more resources